| STAAR Surgical Announces $30 Million Share Repurchase Authorization |
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that its Board of Directors has authorized a share repurchase program under which the Company may repurchase up to $30 million of its outstanding common stock. “Our decision to initiate a share repurchase program underscores the Board's and management's confidence in STAAR's future and. |
businesswire.com |
2025-05-16 11:00:00 |
Czytaj oryginał (ang.) |
| STAAR Surgical Q1: Clouded Outlook Warrants Caution (Rating Downgrade) |
Sales in China were severely impacted due to inventory de-stocking, but the outlook for the region for H2 2025 looks promising. Global sales ex-China were weak, with management choosing to withdraw the earlier guidance for revenue growth of 9–15%. I expect revenue and earnings of $320 million and $23 million, respectively, for next year, which puts the current valuation at 43.5 times earnings. |
seekingalpha.com |
2025-05-14 08:08:34 |
Czytaj oryginał (ang.) |
| STAAR Surgical Company (STAA) Q1 2025 Earnings Call Transcript |
STAAR Surgical Company. (NASDAQ:STAA ) Q1 2025 Earnings Conference Call May 7, 2025 5:15 PM ET Company Participants Brian Moore - VP, Investor Relations and Corporate Development Stephen Farrell - Chair of the Board, President and CEO Warren Faust - President and COO Deborah Andrews - Interim CFO Conference Call Participants Tom Stephan - Stifel Anthony Petrone - Mizuho Ryan Zimmerman - BTIG Patrick Wood - Morgan Stanley Operator Greetings and welcome to the STAAR Surgical First Quarter 2025 Earnings Webcast. |
seekingalpha.com |
2025-05-08 03:51:10 |
Czytaj oryginał (ang.) |
| Staar Surgical (STAA) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates |
Although the revenue and EPS for Staar Surgical (STAA) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. |
zacks.com |
2025-05-08 00:05:50 |
Czytaj oryginał (ang.) |
| Staar Surgical (STAA) Reports Q1 Loss, Tops Revenue Estimates |
Staar Surgical (STAA) came out with a quarterly loss of $0.52 per share versus the Zacks Consensus Estimate of a loss of $0.59. This compares to earnings of $0.06 per share a year ago. |
zacks.com |
2025-05-07 22:45:31 |
Czytaj oryginał (ang.) |
| STAAR Surgical Reports First Quarter 2025 Results |
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today reported results for the first quarter ended March 28, 2025. First Quarter 2025 Financial Overview Net sales of $42.6 million down 45% Y/Y due to planned reduction of channel inventory in China Net Sales Excluding China of $42.2 million up 9% Y/Y reflecting growth in all key markets Gross margin. |
businesswire.com |
2025-05-07 20:01:00 |
Czytaj oryginał (ang.) |
| STAAR Surgical Announces Changes to Board of Directors |
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced changes to its Board of Directors. The Company announced that the Board appointed Louis E. Silverman, who served on the Company's Board from 2014-2022, as a director, effective April 24, 2025. The Company also announced that Aimee S. Weisner, who has served as a director since 2022, has. |
businesswire.com |
2025-04-24 21:00:00 |
Czytaj oryginał (ang.) |
| STAAR Surgical to Host First Quarter 2025 Earnings Conference Call and Webcast on May 7, 2025 |
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that it will release financial results for the first quarter ended March 28, 2025, on Wednesday, May 7, 2025 after the market close. The Company will also host an earnings call and webcast at 5:15 p.m. ET to discuss its financial results and business progress. Event: STAAR Surgical 1Q 2. |
businesswire.com |
2025-04-23 11:00:00 |
Czytaj oryginał (ang.) |
| Tilman Fertitta, Carl Icahn, and More Insiders Return to the Buy Window |
Since the beginning of April, market volatility has spiked, due largely to uncertainty about inflation, interest rates, upcoming quarterly reports, and mostly the impact of tariffs and a global trade war on the U.S. |
247wallst.com |
2025-04-11 12:45:55 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of STAAR Surgical Company. - STAA |
NEW YORK CITY, NY / ACCESS Newswire / March 19, 2025 / Pomerantz LLP is investigating claims on behalf of investors of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accessnewswire.com |
2025-03-19 12:00:00 |
Czytaj oryginał (ang.) |
| STAAR Surgical Announces Realignment of Leadership Structure |
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced the following changes to right size and realign its leadership structure to better address market needs: Warren Foust, Chief Operating Officer, has been promoted to the newly created role of President and Chief Operating Officer. In this expanded role, Mr. Foust will continue to oversee. |
businesswire.com |
2025-03-17 20:30:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of STAAR Surgical Company. - STAA |
NEW YORK , March 17, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ: STAA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
prnewswire.com |
2025-03-17 17:03:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of STAAR Surgical Company. - STAA |
NEW YORK, NY / ACCESS Newswire / March 15, 2025 / Pomerantz LLP is investigating claims on behalf of investors of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accessnewswire.com |
2025-03-15 12:00:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of STAAR Surgical Company. - STAA |
NEW YORK CITY, NY / ACCESS Newswire / March 13, 2025 / Pomerantz LLP is investigating claims on behalf of investors of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accessnewswire.com |
2025-03-13 16:00:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of STAAR Surgical Company. - STAA |
NEW YORK , March 11, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ: STAA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
prnewswire.com |
2025-03-11 14:19:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of STAAR Surgical Company. - STAA |
NEW YORK CITY, NY / ACCESS Newswire / March 9, 2025 / Pomerantz LLP is investigating claims on behalf of investors of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accessnewswire.com |
2025-03-09 12:00:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of STAAR Surgical Company. - STAA |
NEW YORK CITY, NY / ACCESS Newswire / March 7, 2025 / Pomerantz LLP is investigating claims on behalf of investors of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accessnewswire.com |
2025-03-07 12:00:00 |
Czytaj oryginał (ang.) |
| Did STAAR Surgical Company Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate- STAA |
NEW YORK, NY / ACCESS Newswire / March 5, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of STAAR Surgical Company ("STAAR Surgical Company") (NASDAQ:STAA) concerning possible violations of federal securities laws. Staar reported disappointing earnings for Q4 2024, blaming the results on weak demand in China and a drop in refractive procedures. |
accessnewswire.com |
2025-03-05 17:00:00 |
Czytaj oryginał (ang.) |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of STAAR Surgical Company. - STAA |
NEW YORK, NY / ACCESS Newswire / March 5, 2025 / Pomerantz LLP is investigating claims on behalf of investors of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. |
accessnewswire.com |
2025-03-05 16:30:00 |
Czytaj oryginał (ang.) |
| Insiders Are Loading Up on These 6 Stocks Now |
Among the most notable insider purchases of the past week or so is an almost $20 million buy in an American semiconductor concern. |
247wallst.com |
2025-03-05 10:45:48 |
Czytaj oryginał (ang.) |
| STAAR Surgical to Participate in BTIG Ophthalmology Day |
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced that management will participate in meetings with investors and a fireside chat at the 4th Annual BTIG Ophthalmology Day. Event: 4th Annual BTIG Ophthalmology Day Management Attendee: Thomas G. Frinzi, Chair of the Board, President and CEO Date: Monday, Dece. |
businesswire.com |
2024-11-25 09:00:00 |
Czytaj oryginał (ang.) |
| A Dive into Staar Surgical (STAA) International Revenue Trends and Forecasts |
Evaluate Staar Surgical's (STAA) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance. |
zacks.com |
2024-11-04 12:22:32 |
Czytaj oryginał (ang.) |
| STAAR Surgical Company (STAA) Q3 2024 Earnings Call Transcript |
STAAR Surgical Company (NASDAQ:STAA ) Q3 2024 Earnings Conference Call October 30, 2024 4:30 PM ET Company Participants Brian Moore - VP, IR Tom Frinzi - Chair, President and CEO Patrick Williams - CFO Conference Call Participants Tom Stephan - Stifel Ryan Zimmerman - BTIG Patrick Wood - Morgan Stanley Operator Greetings and welcome to the STAAR Surgical Third Quarter 2024 Earnings Webcast. As a reminder, this event is being recorded today Wednesday, October 30th, 2024. |
seekingalpha.com |
2024-10-31 00:57:13 |
Czytaj oryginał (ang.) |
| CORRECTING and REPLACING STAAR Surgical Reports Third Quarter 2024 Results |
LAKE FOREST, Calif.--(BUSINESS WIRE)--The end of the paragraph after bullets in the "Outlook" section of release should read: APAC sales growth of 5% (prior outlook was 7%), including approximately 2% growth in China (prior outlook was 10%) and all other APAC countries approximately 10-20% growth (prior outlook was flat). (Instead of: APAC sales growth of 4% (prior outlook was 7%), including approximately 2% growth in China (prior outlook was 10%). The updated release reads: STAAR SURGICAL REP. |
businesswire.com |
2024-10-31 00:21:00 |
Czytaj oryginał (ang.) |
| Staar Surgical (STAA) Surpasses Q3 Earnings and Revenue Estimates |
Staar Surgical (STAA) came out with quarterly earnings of $0.41 per share, beating the Zacks Consensus Estimate of $0.19 per share. This compares to earnings of $0.30 per share a year ago. |
zacks.com |
2024-10-30 20:37:12 |
Czytaj oryginał (ang.) |
| STAAR Surgical Reports Third Quarter 2024 Results |
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today reported financial results for the third quarter ended September 27, 2024. Third Quarter 2024 Overview Net sales of $88.6 million, up 10% from prior year quarter ICL sales of $89.1 million, up 10% from prior year quarter Gross margin of 77.3% as compared to 79.2% year. |
businesswire.com |
2024-10-30 18:01:00 |
Czytaj oryginał (ang.) |
| STAAR Surgical to Report Third Quarter Results on October 30, 2024 |
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced that it will release financial results for the third quarter ended September 27, 2024, on Wednesday, October 30, 2024, after the market close. Event: STAAR Surgical 3Q 2024 Financial Results Webcast Date: Wednesday, October 30, 2024 Time: 4:30 p.m. ET / 1:30. |
businesswire.com |
2024-10-23 11:00:00 |
Czytaj oryginał (ang.) |
| Here's Why Staar Surgical (STAA) Could be Great Choice for a Bottom Fisher |
Staar Surgical (STAA) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term. |
zacks.com |
2024-10-07 14:56:25 |
Czytaj oryginał (ang.) |
| Fast Money traders share their favorite stocks of the week |
Fast Money traders Steve Grasso, Tim Seymour, Julie Biel, and Mike Khouw share their favorite stocks from this week and explain the reasoning behind their choices. |
youtube.com |
2024-09-27 22:28:14 |
Czytaj oryginał (ang.) |
| Wall Street Analysts Predict a 43.93% Upside in Staar Surgical (STAA): Here's What You Should Know |
The mean of analysts' price targets for Staar Surgical (STAA) points to a 43.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
zacks.com |
2024-09-27 14:57:20 |
Czytaj oryginał (ang.) |
| 4 Stocks to Buy Amid Dental Supplies Industry Challenges |
Here we discuss four stocks from the Dental Supplies industry that are likely to earn wealth for investors. These include BDX, MCK, COO and STAA. |
zacks.com |
2024-09-20 13:35:28 |
Czytaj oryginał (ang.) |
| Staar Surgical (STAA) Moves to Buy: Rationale Behind the Upgrade |
Staar Surgical (STAA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
zacks.com |
2024-09-16 17:00:36 |
Czytaj oryginał (ang.) |
| STAAR Surgical: Expecting A Re-Acceleration In Growth As Investments Materialize |
STAAR Surgical shares are down more than 15% since Q2 earnings, despite management raising full-year revenue guidance. Investments in the US market appear to be yielding promising results, as sales were up 25% year over year. According to my estimates, the company is on track to meet the low end of its 2026 financial targets. |
seekingalpha.com |
2024-09-05 14:41:45 |
Czytaj oryginał (ang.) |
| Why Staar Surgical (STAA) International Revenue Trends Deserve Your Attention |
Evaluate Staar Surgical's (STAA) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance. |
zacks.com |
2024-08-12 14:21:50 |
Czytaj oryginał (ang.) |
| STAAR Surgical Company (STAA) Q2 2024 Earnings Call Transcript |
STAAR Surgical Company (NASDAQ:STAA ) Q2 2024 Earnings Conference Call August 7, 2024 4:15 PM ET Company Participants Brian Moore – Vice President of Investor Relations Tom Frinzi - Chair of the Board, President & Chief Executive Officer Patrick Williams - Chief Financial Officer Conference Call Participants Ryan Zimmerman - BTIG Tom Stephan - Stifel Margaret Kaczor Andrew - William Blair David Saxon - Needham Anthony Petrone - Mizuho George Sellers - Stephens John Young - Canaccord Operator Greetings and welcome to the STAAR Surgical Second Quarter 2024 Earnings Webcast. As a reminder, this event is being recorded today Wednesday, August 7, 2024. |
seekingalpha.com |
2024-08-09 15:49:06 |
Czytaj oryginał (ang.) |
| Staar Surgical (STAA) Reports Q2 Earnings: What Key Metrics Have to Say |
Although the revenue and EPS for Staar Surgical (STAA) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. |
zacks.com |
2024-08-08 01:01:14 |
Czytaj oryginał (ang.) |
| Staar Surgical (STAA) Surpasses Q2 Earnings and Revenue Estimates |
Staar Surgical (STAA) came out with quarterly earnings of $0.33 per share, beating the Zacks Consensus Estimate of $0.25 per share. This compares to earnings of $0.40 per share a year ago. |
zacks.com |
2024-08-07 22:21:03 |
Czytaj oryginał (ang.) |
| Staar Surgical (STAA) Soars 7.5%: Is Further Upside Left in the Stock? |
Staar Surgical (STAA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road. |
zacks.com |
2024-06-27 09:06:52 |
Czytaj oryginał (ang.) |
| Top 4 Stocks With Notable Insider Buying |
Insider buying, where company executives or board members purchase shares of their own company, can be a significant indicator for investors. It often suggests that those closest to the company's operations have confidence in its future performance. |
marketbeat.com |
2024-06-07 13:34:03 |
Czytaj oryginał (ang.) |
| STAAR Surgical to Participate in Goldman Sachs 45th Annual Global Healthcare Conference |
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, invites investors and the general public to listen to a webcast fireside chat with Patrick F. Williams, Chief Financial Officer, at the upcoming Goldman Sachs 45th Annual Global Healthcare Conference, which will be held in Miami, Florida. Patrick F. Williams, Chief Financia. |
businesswire.com |
2024-06-05 11:00:00 |
Czytaj oryginał (ang.) |